Qiagen (NYSE:QGEN) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lessened its holdings in Qiagen (NYSE:QGEN) by 52.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 161,325 shares of the company’s stock after selling 177,517 shares during the quarter. Voya Investment Management LLC’s holdings in Qiagen were worth $7,185,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in QGEN. Brown Brothers Harriman & Co. acquired a new stake in Qiagen in the 4th quarter worth approximately $37,000. Geneos Wealth Management Inc. raised its holdings in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after buying an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after buying an additional 526 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Qiagen during the third quarter valued at $53,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock valued at $63,000 after acquiring an additional 835 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Up 0.3 %

NYSE QGEN opened at $42.61 on Wednesday. The business has a fifty day moving average price of $40.10 and a 200 day moving average price of $41.71. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The company has a market cap of $9.47 billion, a P/E ratio of 118.65, a P/E/G ratio of 2.39 and a beta of 0.62. Qiagen has a one year low of $37.63 and a one year high of $49.30.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. Research analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on QGEN shares. Morgan Stanley reiterated an “equal weight” rating and set a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Redburn Atlantic lowered Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. UBS Group reduced their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird boosted their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus target price of $47.83.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.